
...
By Zach Pressnell
Contributing Sports Writer
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
The Toronto Blue Jays have surprised the entire league this season. Rather than sitting as a borderline postseason contender at the trade deadline, Toronto sits atop the American League and leads the A.L. East by multiple games.
And the Blue Jays have done this with a bad pitching staff.
At the trade deadline, Toronto will almost certainly look to add some arms to the bullpen as well as a starting pitcher or two to the rotation.
Read More on MLB
Bleacher Report's Zachary Rymer recently suggested the Blue Jays were the best fit in a trade for Miami Marlins ace Sandy Alcántara in the coming days.

...
"Apropos of that last note, Alcantara's fiendish-looking 6.66 ERA isn't the only thing casting a cloud over his trade value," Rymer wrote. "The 2022 NL Cy Young Award winner also already has 104 innings on his arm in his first year back from Tommy John surgery. As Patrick Mooney and Will Sammon pondered for The Athletic, how much he'll have left for October is a real concern."
"The righty has shown flashes of his old brilliance here and there, though, and any trade for him won't need to pay off in 2025 alone. He is signed for 2026 with a club option for 2027. That is part of what makes him a good fit for the Padres, but there are two reasons why he's a better fit for a Blue Jays team that is in first place despite a rotation ERA of 4.52."
Toronto has the farm system to make a deal for Alcántara. He's not pitching like his old self all the time, but there have been flashes of his Cy Young level production from time-to-time this season.
The Blue Jays would need to put together a solid package of prospects to land the veteran righty, but it's something they need to do if they want to contend for the AL pennant and World Series in October.
More MLB: Diamondbacks Predicted To Trade $18 Million Pitcher After Josh Naylor Deal
View 0 Comments
Submit Correction
View Editorial & AI Guidelines